Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04085029 · ClinicalTrials.gov registry record
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
A clinical trial of Metastatic Cancer and Oligometastasis, sponsored by Duke University.
- Recruiting
- Registry status
- 300
- Enrollment target
- 5
- Study locations
NCT04085029: Recruiting study of Metastatic Cancer and Oligometastasis, sponsored by Duke University.
NCT04085029 is a study of Metastatic Cancer and Oligometastasis that is actively recruiting participants, run by Duke University. The registered enrollment target is 300 participants, below the 441-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (32% lower). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04085029, a study of Metastatic Cancer and Oligometastasis, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Conditions Studied
Study Locations (5)
North Carolina
- Duke Cancer Institute Cary - Cary
- Durham Veterans Administration Health Care System (DVAHCS) - Durham
- Duke University Medical Center - Durham
- Duke Women's Cancer Care Raleigh - Raleigh
- Duke Raleigh Hospital - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-09-26 |
| Est. Completion | 2029-09 |
What NCT04085029 shows while recruiting
NCT04085029 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 441-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (32% lower).
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04085029 lists 5 locations in 1 state (North Carolina).
Frequently Asked Questions
What is clinical trial NCT04085029 about?
NCT04085029 is a clinical study titled "Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry". The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
What is the current status of trial NCT04085029?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2019-09-26. Estimated completion is 2029-09.
What conditions does trial NCT04085029 study?
This clinical trial studies the following conditions: Metastatic Cancer, Oligometastasis.
Who is sponsoring clinical trial NCT04085029?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04085029 being conducted?
This trial has 5 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04085029's enrollment target sits among peer trials
300 16th of 109 higher than 93 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI